ReviewStem cells translational medicine2026
Molecular time machines unleashed: small-molecule-driven reprogramming to reverse the senescence.
Review in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Skeletal muscle reprogramming in peripheral nerve injury: mechanisms, therapeutic roles, and complication management.Experimental biology and medicine (Maywood, N.J.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cellular reprogramming, a method of "resetting" the epigenetic clock by reversing the differentiation state of cells, has emerged as a promising approach to anti-aging, offering new strategies to slow down the aging process. Researchers convert differentiated cells into a pluripotent stem cell state through transcription factors or chemicals, restoring cellular youthfulness and regenerative capacity. This technology holds potential for tissue repair, lifespan extension, organ function improvement, and treatment of age-related diseases. In addition, cell reprogramming provides a novel pathway for disease modeling and drug screening, potentially accelerating the development and clinical application of anti-aging drugs. However, it faces challenges including safety, efficiency, and ethical considerations. This article focuses on the prospects of small-molecule-induced cell reprogramming for anti-aging, covering its mechanisms, applications, current limitations, and future directions to facilitate clinical translation and breakthroughs in human healthspan extension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.